Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

Shares of Hims & Hers Health (NYSE: HIMS) have been on fire over the past year, but they're not expensive by most valuation ...

Hims & Hers Health (NYSE: HIMS) reported another blowout quarter recently, but the stock didn't get the type of pop that ...

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

Investors with a lot of money to spend have taken a bullish stance on Hims & Hers Health HIMS. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

On Friday, Hims & Hers Health Inc (HIMS) stock saw a decline, ending the day at $23.41 which represents a decrease of $-0.21 or -0.89% from the prior close of $23.62. The stock opened at $23.6 and ...

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...

Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

Hims & Hers is revolutionizing telehealth and wellness for millennials and Gen Z with rapid revenue growth and positive net ...